Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase - Still a Buy?

Key Points

• Nanobiotix's shares experienced a significant increase in trading volume, with about 34,552 shares traded, a 23% rise from the previous session.
• Wall Street analysts have mixed views on the stock, with two recommending a Buy, one a Hold, and one a Sell; the average target price is set at $11.00.
• Nanobiotix is focused on developing cancer treatments, with its lead product candidate, NBTXR3, aimed at various types of cancer including soft tissue sarcoma and prostate cancer.

Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) saw unusually-high trading volume on Monday . Approximately 34,552 shares traded hands during trading, an increase of 23% from the previous session's volume of 28,006 shares.The stock last traded at $25.06 and had previously closed at $25.60.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NBTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a report on Wednesday, October 8th. Leerink Partners set a $14.00 price target on shares of Nanobiotix in a report on Thursday, September 18th. Finally, HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a report on Friday, September 19th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Nanobiotix has an average rating of "Hold" and an average target price of $11.00.

Nanobiotix Trading Down 3.5%

The stock's 50-day moving average price is $14.16 and its 200-day moving average price is $7.87.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.